ALGS Stock Summary and Trading Ideas (Aligos Therapeutics | NASDAQ:ALGS)

Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.

Aligos Therapeutics trades on the NASDAQ stock market under the symbol ALGS.

As of November 3, 2026, ALGS stock price climbed to $4.75 with 11,993 million shares trading.

ALGS has a beta of 1.44, meaning it tends to be more sensitive to market movements. ALGS has a correlation of 0.04 to the broad based SPY ETF.

ALGS has a market cap of $29.66 million. This is considered a Sub-Micro Cap stock.

Last quarter Aligos Therapeutics reported $0 in Revenue and -$.14 earnings per share. This fell short of revenue expectation by $-19 million and exceeded earnings estimates by $1.14.

In the last 3 years, ALGS traded as high as $46.80 and as low as $3.76.

The top ETF exchange traded funds that ALGS belongs to (by Net Assets): VTI, VXF, IWC, DFMC, DFAS.

ALGS has underperformed the market in the last year with a price return of -42.4% while the SPY ETF gained +11.7%. However, in the short term, ALGS had mixed performance relative to the market. It has outperformed in the last 3 months, returning +12.3% vs +1.2% return in SPY. But in the last 2 weeks, ALGS shares have been beat by the market, returning -1.9% compared to an SPY return of -1.6%.

ALGS support price is $4.30 and resistance is $4.90 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ALGS shares will trade within this expected range on the day.